Pre ukladanie filtrov sa prosím prihláste.
Počet výsledkov: 17
“My job is to be a guardian of patient safety.”
Renal cell carcinoma (RCC) has seen remarkable scientific progress over the past decade. Advances in immunotherapy, targeted agents, and combination strategies have reshaped the treatment landscape and transformed outcomes for many patients. Yet for people living with the most common form of kidney…
Progressive Familial Intrahepatic Cholestasis (PFIC) can be a complex condition. Finding trusted information about PFIC shouldn’t be. PFIC Colors is designed to help families make sense of these conditions and find the information and support they need, fast.
Acute myeloid leukaemia (AML) remains a difficult blood cancer to treat. Despite progress, relapse is still common and long-term disease control remains out of reach for many, especially older patients or those who cannot receive intensive chemotherapy. As we learn more about AML, we are seeing…
Science has changed – the best deals evolve with it.
By mobilizing the right partners across our value chain and engaging our employees to move forward together.
Ipsen’s 2025 Integrated Annual report report is now available on Ipsen.com. This essential reference document brings together key information and insights into the major developments in 2025 and what lies ahead.
